We are live on ! Find out more
MGNX icon

MacroGenics

144 hedge funds and large institutions have $531M invested in MacroGenics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,211% more call options, than puts

Call options by funds: $498K | Put options by funds: $38K

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

4.96% more ownership

Funds ownership: 93.38%98.34% (+5%)

8% less funds holding

Funds holding: 156144 (-12)

38% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 32

42% less capital invested

Capital invested by funds: $918M → $531M (-$387M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
144
Holders Change
-12
Holders Change %
-7.69%
% of All Funds
2.26%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
20
Increased
58
Reduced
38
Closed
32
Calls
$498K
Puts
$38K
Net Calls
+$460K
Net Calls Change
-$160K

MGNX Hedge Fund Activity: Q1 2022 in Review

144 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q1 2022, worth a combined $531M — down 42% from $918M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of MGNX and 20 opened new positions — a net loss of 12 holders — while 38 trimmed existing stakes and 58 added.

The largest buyer was Armistice Capital, adding an estimated $25.4M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $20.2M sold.

  • 144 institutional investors held MacroGenics (MGNX) as of Q1 2022, down from 156 in Q4 2021.
  • Funds reported $531M of MacroGenics stock for Q1 2022, down 42% quarter-over-quarter.
  • 20 funds opened new MacroGenics positions in Q1 2022 and 32 closed out, a net change of -12 holders.
  • The largest MacroGenics buyer in Q1 2022 was Armistice Capital, an estimated $25.4M added.
  • The largest MacroGenics seller in Q1 2022 was Point72 Asset Management, an estimated $20.2M sold.

Based on aggregated 13F filings for Q1 2022.